Njie GJ, et al. - Researchers compared 3-month isoniazid-rifapentine treatment regimen with other latent tuberculosis infection (LTBI) regimens primarily comprising 9-month isoniazid treatment with respect to efficacy, safety, and treatment completion. Analysis of most recent evidence in this regard revealed equal safety and effectiveness of the short-course 3-month isoniazid-rifapentine treatment regimen as has been observed with other LTBI regimens. Moreover, when administered by directly observed therapy (DOT) and self-administered therapy (SAT), 3-month isoniazid-rifapentine treatment achieved higher treatment completion rates. Moreover, 3-month isoniazid-rifapentine treatment was proved to be safe and effective for healthy adults, children aged more than 2 years, adolescents, and people living with HIV/AIDS (PLWHA). Solid-organ transplant candidates well-tolerated a 3-month combination of isoniazid and rifapentine.